2Van Staa T, Abenhaim L, Monette J, et al. Rates of hypoglycemia in users of sulfonylureas[J]. J Clin Epidemiol, 1997, 50(6): 735-741.
3UKPDS-33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group[J]. Lancet, 1998, 52(9131 ): 837-853.
4Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people[J]. J Am Geriatr Soc, 1996, 44(7): 751-755.
5Gangji AS, Cukierman T, Gerstein HC, et al. Systematic review and meta- analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin[J]. Diabetes Care, 2007, 30(2): 389-394.
6Fravel MA, McDanel DL, Ross MB, et al. Special considerations for treatment of type 2 diabetes mellitus in the elderly[J]. Am J Health Syst Pharm, 2011, 68(6): 500-509.
7Riddle MC, McDaniel PA, Tive LA. Glipizide-GITS does not increase the hypoglycemie effect of mild exercise during fasting in NIDDM[J]. Diabetes Care, 1997, 20(6): 992-994.
10Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double- blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients[J]. Eur J Clin Invest, 2004, 3(8): 535-542.
二级参考文献32
1Peter P, Frank R, Nick G, et al. Sulfonylurea stimulation of in aulin secretion. Diabetes, 2002,51 ( Suppl 3): S368-S376.
2Garratt KN, Brady PA, Haasinger NL, et al. Sulfonylurea drugs increase early motality in patients with diabetes mellitus after direct angioplasty for acute myocardial infaction. J Am Cell Cardiol, 1999,33:119-124.
3Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev,2000,21:585-618.
4Davis TM, Parsons RW, Broadburst R J, et al. Arrhythmias and mortality after myocardial infaction in diabetic patients: relationship to diabetes treatment. Diabetes Care, 1998,21:637-640.
5Renstrom E, Barg S, Thevenod F, et al. Sul.fonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K + channel-independent action. Diabetes, 2002,51 (Suppl 1 ): S33-S36.
6Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic suffonylurea drug Amaryl. Mol Med, 2000,6:907-933.
7Dills DG, Schneider J. Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res, 1996,28:426-429.
8Muller G. Dynamics of plasma membrane microdomains and cross-talk to the insulin signalling cascade. FEBS Lett, 2002,531: 81-87.
9DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 1999,131:281-303.
10Richard A, Michelle S, Phillip B. Oral agents for the treatment of type 2diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emeg Med,2001,38:68-78.
4Holstein A,Patzer OM,Machalke K. Substantial Increase in Incidence of Severe Hypoglycemia Between 1997-2000 and 2007-2010 A German longitudinal population-based study[J].Diabetes Care,2012,(05):972-975.
5Manolopoulos VG,Ragia G,Tavridou A. Pharmacogenomics of oral antidiabetic medications:current data and pharmacoepigenomic perspective[J].Pharmacogenomics,2011,(08):1161-1191.
6Becker ML,Aarnoudse AJ,Newton-Cheh C. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea[J].Pharmacogenetics and Genomics,2008,(07):591-597.doi:10.1097/FPC.0b013e328300e8c5.
7Feng Y,Mao G,Ren X. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients[J].Diabetes Care,2008,(10):1939-1944.doi:10.2337/dc07-2248.
8Holstein A,Hahn M,Stumvol M. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes[J].Hormone and Metabolic Research,2009,(05):387-390.doi:10.1055/s-0029-1192019.
9Hamming K,Soliman D,Matemisz LC. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+channel[J].Diabetes,2009,(10):2419-2424.
10Zhang Y,Si D,Chen X,et a1. Influence of CYP2C9 and CYP2C1 9 genetic Polymorphism on pharmacokinetics of gliclazide MR in Chinese subjects[J].British Journal of Clinical Pharmacology,2007,(01):67-74.doi:10.1111/j.1365-2125.2007.02846.x.
